
ACR News
ACRES Commercial Realty Corp.
$8.40
+$0.05(+0.60%)
41
Overall
40
Value
36
Tech
47
Quality
Market Cap
$113.00M
Volume
50.78K
52W Range
$8.80 - $24.61
Target Price
$17.00
ACR news: the latest ACRES Commercial Realty Corp. headlines, press releases and market updates, newest first.
Latest ACR News
- Acrux announces CFO and Company Secretary appointmentsTipRanks Australian Auto-Generated Newsdesk · Nov 19, 2026
- Aclaris Advances Modzatinib Trial in Lichen Planus: What ACRS Investors Should KnowTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 18, 2026
- Accor Agrees to Increase Stake in EnnismoreTipRanks European Auto-Generated Newsdesk · Nov 17, 2026
- Analysts Are Bullish on These Healthcare Stocks: Oric Pharmaceuticals (ORIC), Acrivon Therapeutics, Inc. (ACRV)TipRanks Newsroom · Nov 17, 2026
- Analysts Offer Insights on Real Estate Companies: Welltower (WELL) and Ares Commercial (ACRE)TipRanks Newsroom · Nov 16, 2026
- Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), GH Research (GHRS) and Lantheus (LNTH)TipRanks Newsroom · Nov 16, 2026
- Analysts Are Bullish on Top Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Acrivon Therapeutics, Inc. (ACRV)TipRanks Newsroom · Nov 11, 2026
- Acrivon Therapeutics Hosts Webcast Introducing New Immunology ProgramsTipRanks Auto-Generated Newsdesk · Nov 10, 2026
- Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), COMPASS Pathways (CMPS) and Zenas BioPharma, Inc. (ZBIO)TipRanks Newsroom · Nov 9, 2026
- Wedbush Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)TipRanks Auto-Generated Intelligence Newsdesk · Nov 9, 2026
- ACRES Commercial Realty Earnings Call Signals Cautious ProgressTipRanks Auto-Generated Newsdesk · Nov 7, 2026
- ACRES Commercial Realty Extends Morgan Stanley Financing FacilityTipRanks Auto-Generated Newsdesk · Nov 6, 2026
- Oppenheimer Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)TipRanks Auto-Generated Intelligence Newsdesk · Nov 6, 2026
- Acrivon Acquires Aqilion’s JAK1 and PKCθ Inhibitor ProgramsTipRanks Auto-Generated Newsdesk · Nov 6, 2026
- Ares Commercial Reports Third-Quarter Results and DividendTipRanks Auto-Generated Newsdesk · Nov 6, 2026
- Acrux Reports Expiry of 144,000 Performance RightsTipRanks Australian Auto-Generated Newsdesk · Nov 3, 2026
- Acrux Seeks ASX Quotation of 100,000 SharesTipRanks Australian Auto-Generated Newsdesk · Nov 3, 2026
- LACROIX Revenue Rises 3.2% as Environment Drives GrowthTipRanks European Auto-Generated Newsdesk · Nov 2, 2026
- Oppenheimer Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)TipRanks Auto-Generated Intelligence Newsdesk · Oct 28, 2026
- Aclaris Therapeutics Announces New $46.7M Equity OfferingTipRanks Auto-Generated Newsdesk · Oct 27, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACR | $8.40 | +0.6% | 50.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ACRES Commercial Realty Corp. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW